Surge-Capable Domestic Biomanufacturing

The contract seeks to establish large-scale domestic manufacturing of dermal substitutes in the United States with built-in surge capacity to support mass casualty and emergency response scenarios. The effort is focused on creating a resilient, onshore production capability capable of rapidly scaling output during public health emergencies, ensuring timely availability of critical wound care products when demand spikes. This initiative is aligned with national preparedness goals and underscores a strategic push to reduce reliance on overseas supply chains for life-saving medical materials. The award is structured as a subcontract under the Administration for Strategic Preparedness and Response within the Department of Health and Human Services, with a North American Industry Classification System code of 325411 for pharmaceutical and medicine manufacturing. The solicitation was posted on July 28, 2026, and responses are due by August 28, 2026. Although the place of performance is listed with a zip code of 77416, no specific city or state is provided, and no point of contact details are included. The contract does not specify a set-aside status, indicating it is open to all qualified entities regardless of size or ownership. The focus remains on achieving domestic production capacity that can maintain steady output and immediately ramp up during crises.